This is a list of all the questions and their associated study carrel identifiers. One can learn a lot of the "aboutness" of a text simply by reading the questions.
| identifier | question |
|---|---|
| cord-014875-xhzxhwgo | Where does this lead us? |
| cord-017062-dkw2sugl | the fi rst 10 cases reported in the United States Fatal inhalational anthrax in a 94-year- old Connecticut woman Extrapulmonary tuberculosis: clinical and epidemiologic spectrum of 636 cases Nanoparticles for drug delivery in cancer treatment Polymeric drugs for effi cient tumor- targeted drug delivery based on EPR- effect Exploiting the enhanced permeability and retention effect for tumor targeting Drug targeting and tumor heterogeneity Does a targeting ligand infl uence nanoparticle tumor localization or uptake? |
| cord-016283-b6yywn9f | Worth a try in extensively drug- resistant tuberculosis? |
| cord-000182-ni6iyzdn | CYP1A1: friend or foe? |
| cord-252147-bvtchcbt | Is declining innovation in the pharmaceutical industry a myth? |
| cord-104431-3rblzyry | responding to covid-19-a once- in- a- century pandemic? |
| cord-017583-72mbsib7 | an approach to immunobiology Regulating the regulators Regulatory T cells: friend or foe in immunity to infection? |
| cord-104493-yqf7tyo4 | 2 Ribavirin in the treatment of SARS: A new trick for an old drug? |
| cord-258128-qtmjgrml | a prospective observational study Clinical practice guidelines for diagnosis and management of cough- Chinese Thoracic Society( CTS) Asthma Consortium Pharmacology of dextromethorphan: relevance to dextromethorphan/ quinidine( Nuedexta ®) clinical use Hypothesis: angiotensin- converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19 SARS- CoV2: should inhibitors of the renin- angiotensin system be withdrawn in patients with COVID-19? |
| cord-253115-ekgdsv4f | In vivo tumor targeting via nanoparticlemediated therapeutic siRNA coupled to inflammatory response in lung cancer mouse models Novobrantseva, siRNA and the lung: research tool or therapeutic drug? |
| cord-255895-6at9gelt | Good or bad? |
| cord-270516-9ol1209i | Enhanced neuronal cell differentiation combining biomimetic peptides and a carbon nanotube- polymer scaffold Antibacterial activity and cytotoxicity of multi- walled carbon nanotubes decorated with silver nanoparticles Mechanisms of pulmonary toxicity and medical applications of carbon nanotubes: two faces of janus? |
| cord-001072-pjv3wy80 | Microneedle technologies for( trans)dermal drug and vaccine delivery Techniques of tissue handling and transfer Intradermal vaccine delivery: will new delivery systems transform vaccine administration? |
| cord-001072-pjv3wy80 | effects of dosage and route on safety and immunogenicity Electroporation as a"prime/ boost"strategy for naked DNA vaccination against a tumor antigen Vaxfectin- formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge DNA vaccines: ready for prime time? |
| cord-016309-6mw8okmt | Combination chemotherapy: interaction of 5-methoxymethyldeoxyuridine with adenine arabinoside, 5-ethyldeoxyuridine, 5-iododeoxyuridine, and phosphonoacetic acid against herpes simplex virus types 1 and 2 Single- chain fragment variable antibody against the capsid protein of bovine immunodeficiency virus and its use in ELISA Cham Bracklein T et al( 2006) Activity of feline interferon- omega after ocular or oral administration in cats as indicated by Mx protein expression in conjunctival and white blood cells High- content screening in infectious diseases History and progress of antiviral drugs: from acyclovir to directacting antiviral agents( DAAs) for Hepatitis C Natural products to drugs: natural product- derived compounds in clinical trials Efficacy, toxicology and clinical applications of ribavirin against virulent RNA viral infections Synthesis and antiviral evaluation of trisubstituted indole N- nucleosides as analogues of 2, 5, 6-trichloro-1-(β- D- ribofuranosyl) benzimidazole( TCRB) Expression and characterization of a recombinant porcinized antibody against the E2 protein of classical swine fever virus Drug repurposing: new treatments for zika virus infection? |
| cord-016309-6mw8okmt | Synthesis and antiviral activity Is AZT/3TC therapy effective against FIV infection or immunopathogenesis? |
| cord-016460-39yniw0t | Attacks of FMF? |
| cord-016460-39yniw0t | Colchicine use in cyclosporine treated transplant recipients: how little is too much? |
| cord-257144-3q0un5rl | efficiently suppresses inflammatory responses of human class- switched memory B cells via toll- like receptor 9 inhibition Cutting edge: antimalarial drugs inhibit IFN- b production through blockade of cyclic GMP- AMP synthase- DNA interaction Modulating lysosomal function through lysosome membrane permeabilization or autophagy suppression restores sensitivity to cisplatin in refractory nonsmall- cell lung cancer cells Mechanism of action of Hydroxychloroquine as an Antirheumatic drug Autophagy in immunity and inflammation Inhibition of macroautophagy triggers apoptosis DNA sensing by the cGAS- STING pathway in health and disease Smooth or risky revisit of an old malaria drug for COVID-19? |
| cord-007511-5d5authn | Coartem( artemether- lumefantrine) in Africa: the beginning of the end? |
| cord-007511-5d5authn | amodiaquine regimens efficacy& safety? |
| cord-214795-8jweuq50 | A deep matrix factorization method for learning attribute representations Arbidol: A potential antiviral drug for the treatment of SARS- CoV-2 by blocking the trimerization of viral spike glycoprotein? |
| cord-272060-o0wx0add | The Effects of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Volunteers: A Single- Sequence Crossover Study Postmarketing safety surveillance: where does signal detection using electronic healthcare records fit into the big picture? |
| cord-015684-q10sx1dm | HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? |
| cord-015684-q10sx1dm | The functional genome of CA1 and CA3 neurons under native conditions and in response to ischemia Fibroblast and lymphoblast gene expression profi les in schizophrenia: are non- neural cells informative? |
| cord-256852-lrz17bdx | Could and should WHO be the lead organization in curbing the spreading epidemic of falsified pharmaceuticals? |
| cord-256852-lrz17bdx | How would the convention work and what national benefits would it bring? |
| cord-267608-0odu8lus | imatinib[ 6, 40] Assessing the gold standard-- lessons from the history of RCTs Cancer clinical trials: the rear- view mirror and the crystal ball Adaptive designs for clinical trials chemisimilars and biosimilars: is clinical testing fit for purpose? |
| cord-267608-0odu8lus | retrospective cohort study Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs? |
| cord-283956-zgrtux7i | One Health Chloroquine: mechanism of drug action and resistance in Plasmodium falciparum New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? |
| cord-281561-r10y2sgb | : what's next? |
| cord-263803-0n41gylj | How does the quality of phospholipidosis data influence the predictivity of structural alerts? |
| cord-263803-0n41gylj | This raised a compelling question: do the pharmacological treatment of these patients play a role in the observed protective effect? |
| cord-275772-pmf6stua | Can you teach old drugs new tricks? |
| cord-006226-fn7zlutj | What kind of study should be performed( e. g. cost- effectiveness, cost- utility, cost- benefit analysis)? |
| cord-006226-fn7zlutj | Which objectives should be considered? |
| cord-006226-fn7zlutj | Who should perfom a pharmacoeconomic study? |
| cord-102823-zult69f2 | How powerful are graph neural networks? |
| cord-102823-zult69f2 | Protein kinases- the major drug targets of the twenty- first century? |
| cord-280819-z6ucnwk0 | New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? |
| cord-302947-flgwxc57 | incovid-19: a single center experience Effective treatment of severe COVID-19 patients with tocilizumab Interleukin-6 and cytochrome- P450, reason for concern? |
| cord-264779-71s7e18i | paramyxoviruses Mitochondrial toxicity of antiviral drugs Mechanism of inhibition of Ebola virus RNA- dependent RNA polymerase by remdesivir Gilead Sciences statement on request to rescind remdesivir orphan drug designation Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? |
| cord-276886-vcmkz8lh | The tug- ofwar between toxicity and therapeutic efficacy can invariably be won by the body, thanks to our immune system, but is it the'best in class'solution for a particular medical problem? |
| cord-263074-qxiynbl2 | How can nanoparticles contribute to antituberculosis therapy? |
| cord-263074-qxiynbl2 | Recent therapeutic approaches for the management of tuberculosis: challenges and opportunities How can nanoparticles contribute to antituberculosis therapy? |
| cord-033723-jy5fdsp9 | Where are you going to? |
| cord-033723-jy5fdsp9 | where have you been? |
| cord-298369-66ifwtlp | Do we need to optimize plasma and tissue binding in drug discovery? |
| cord-291180-xurmzmwj | Are we nearly there yet? |
| cord-001470-hn288o97 | : Framework for evaluating public health surveillance systems for early detection of outbreaks: recommendations from the CEC working group Review of syndromic surveillance: implications for waterborne disease detection Absenteeism in schools during the 2009 influenza A(H1N1) pandemic: a useful tool for early detection of influenza activity in the community? |
| cord-001470-hn288o97 | Using oral vancomycin prescriptions as a proxy measure for Clostridium difficile infections: a spatial and time series analysis Surveillance data for waterborne illness detection: an assessment following a massive waterborne outbreak of Cryptosporidium infection Pharmaceutical sales; a method for disease surveillance? |
| cord-001470-hn288o97 | What is syndromic surveillance? |
| cord-004501-guiy89x8 | Up to now we have concluded that current antiviral therapy has not yet achieved the ideal shape and efficiency and also that the complex biological barriers are major obstacles, but can we critically say that nanotechnology could be the identified solution? |
| cord-004501-guiy89x8 | Viral pneumonia La Revue de Médecine Interne Viral myocarditis Viral infections in type 1 diabetes mellitus- Why the β cells? |
| cord-178783-894gkrsk | A Reasoning And Hypothesis- Generation Framework Based On Scalable Graph Analytics Enabling Discoveries Link prediction on the semantic medline network Are abstracts enough for hypothesis generation? |
| cord-178783-894gkrsk | The trinity of COVID-19: immunity, inflammation and intervention COVID-19: coagulopathy, risk of thrombosis, and the rationale for anticoagulation The role of TLR4 in chemotherapy- driven metastasis Is Tolllike receptor 4 involved in the severity of COVID-19 pathology in patients with cardiometabolic comorbidities? |
| cord-283287-073r80s7 | Are evidencebased indicators an achievable goal? |
| cord-283287-073r80s7 | COVID-19: What is next for public health? |
| cord-301026-spgidqh3 | Once- in- a- Century Pandemic? |
| cord-017702-v46ye328 | Should we use N- acetyltransferase type 2 genotyping to personalize isoniazid doses? |
| cord-017702-v46ye328 | can genetics help guide treatment? |
| cord-017702-v46ye328 | can pharmacogenomics improve malaria drug policy? |
| cord-035236-7rfc73qb | Consecutively alternating adsorption of anionic and cationic polyelectrolytes on charged surfaces Fuzzy nanoassemblies: toward layered polymeric multicomposites Multilayers of colloidal particles Layer- by- layer self assembly of polyelectrolytes on colloidal particles Biocompatible long- sustained release oil- core polyelectrolyte nanocarriers: from controlling physical state and stability to biological impact Encapsulation of liquid cores by layer- by- layer adsorption of polyelectrolytes Nanoparticle synthesis in engineered organic nanoscale reactors Monodisperse polyelectrolyte- supported asymmetric lipid- bilayer vesicles Bioinspired colloidal systems via layer- by- layer assembly Which polymers can make nanoparticulate drug carriers long- circulating? |
| cord-035236-7rfc73qb | In vivo distribution of polymeric nanoparticles at the whole- body, tumor, and cellular levels Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology Nanodrug delivery: is the enhanced permeability and retention effect sufficient for curing cancer? |
| cord-035236-7rfc73qb | Injectable lipid- based depot formulations: where do we stand? |
| cord-032561-x3qbqy69 | Can We Go? |
| cord-032561-x3qbqy69 | Reactive oxygen species responsive nanoplatforms as smart drug delivery systems for gastrointestinal tract targeting pH and Reactive Oxygen Species- Sequential Responsive Nano- in- Micro Composite for Targeted Therapy of Inflammatory Bowel Disease Nanoparticulate drug delivery systems targeting inflammation for treatment of inflammatory bowel disease Drug delivery strategies in the therapy of inflammatory bowel disease Short- term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis Inflammation in Neurological Disorders: A Help or a Hindrance? |
| cord-001244-qdld7hdc | During the process of developing drugs against these diseases by targeting NRs, we are often facing a problem: Given a NR and chemical compound, can we identify whether they are really in interaction with each other in a cell? |
| cord-001244-qdld7hdc | Facing such a dilemma, can we find an approach to partially incorporate the sequence- order effects? |
| cord-001244-qdld7hdc | What are genetic studies telling us their role in renal life? |
| cord-001244-qdld7hdc | correlative effect Does the folding type of a protein depend on its amino acid composition? |
| cord-284648-yznlgzir | Biomedical applications of tunable biopolymers Molecular Description of the LCST Behavior of an Elastin- Like Polypeptide UCST and LCST behavior in polymer blends A unified model for de novo design of elastin- like polypeptides with tunable inverse transition temperatures Temperature dependence of length of elastin and its polypentapeptide Effect of protein fusion on the transition temperature of an environmentally responsive elastin- like polypeptide: a role for surface hydrophobicity? |
| cord-261170-arnwk287 | If you were required to evaluate an extract for its potential as a drug, what approach would you adopt? |
| cord-261170-arnwk287 | The exploitation of an old natural resource with sustainable and novel methods Marine natural products: A new wave of drugs? |
| cord-261170-arnwk287 | and what are we bioprospecting? |
| cord-203191-7ftg6bfx | How Far Are We? |
| cord-203191-7ftg6bfx | The landscape of lung bronchoalveolar immune cells in COVID-19 revealed by single- cell RNA sequencing Renovation as innovation: is repurposing the future of drug discovery research? |
| cord-288026-vcp8o5xn | Clinical efficacy and effectiveness of 3D printing: a systematic review Role of innovative 3D printing models in the management of hepatobiliary malignancies Organ printing: the future of bone regeneration? |
| cord-288026-vcp8o5xn | Colloids and surfaces Antibacterial Activity and Cytotoxicity of Immobilized Glucosamine/ Chondroitin Sulfate on Polylactic Acid Films Threedimensional printing surgical instruments: are we there yet? |
| cord-304617-5ozf18lg | What lessons have we learned? |
| cord-018595-x3tleomb | Pseudoporphyria induced by voriconazole Pseudoporphyria induced by propionic acid derivatives Diclofenac- induced pseudoporphyria; an under- recognized condition? |
| cord-018595-x3tleomb | Results from the prospective RegiSCAR study Drug reaction with eosinophilia and systemic symptoms: is cutaneous phenotype a prognostic marker for outcome? |
| cord-018595-x3tleomb | Variability in the clinical pattern of cutaneous side- effects of drugs with systemic symptoms: does a DRESS syndrome really exist? |
| cord-018595-x3tleomb | What is a serious adverse event? |
| cord-302312-1pm17l5d | What's in the pipeline? |
| cord-316029-z708c3ex | Does beta- lactam pharmacokinetic variability in critically ill patients justify therapeutic drug monitoring? |
| cord-263840-1t4ykc01 | COVID-19 and angiotensin- converting enzyme inhibitors and 446 angiotensin receptor blockers: what is the evidence? |
| cord-263840-1t4ykc01 | clinical- grade soluble human ACE2 Human coronavirus EMC does not require the SARS- coronavirus 437 receptor and maintains broad replicative capability in mammalian cell lines Renovation as innovation: is repurposing 439 the future of drug discovery research? |
| cord-263840-1t4ykc01 | methods and applications Tocilizumab for the treatment of chimeric antigen 411 receptor T cell- induced cytokine release syndrome A crucial role of angiotensin converting enzyme 2( ACE2) in SARS coronavirus- induced lung 414 injury Drug repurposing: a better approach for 416 infectious disease drug discovery? |
| cord-289321-ahl46ql9 | In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms Complete replication of hepatitis C virus in cell culture Novel therapies for hepatitis C-one pill fits all? |
| cord-289321-ahl46ql9 | What does cis- dominant resistance mean mechanistically? |
| cord-299400-j18pj11d | comparison with lysosomotropic drugs Effects of chloroquine on viral infections: an old drug against today's diseases? |
| cord-257496-mirh80gn | Is global BCG vaccination coverage relevant to the progression of SARS- CoV2 pandemic? |
| cord-257496-mirh80gn | Scope and relevance of a pulmonary biopharmaceutical classification system AAPS/ FDA/ USP Workshop March 16- 17th Ste20-like kinase- mediated control of actin polymerization is a new mechanism for thin filament associated regulation of airway smooth muscle contraction Use of non- invasive ventilation for patients with COVID-19: a cause for concern? |
| cord-252166-qah877pk | A return to rational drug discovery: computer- based models of cells, organs and systems in drug target identification Homology modeling of the serotonin 5-HT1A receptor using automated docking of bioactive compounds with defined geometry Computational tools for the analysis and visualization of multiple protein- ligand complexes Renin inhibition by substituted piperidines: a novel paradigm for the inhibition of monomeric aspartic proteinases? |
| cord-252166-qah877pk | Can we estimate the accuracy of ADME- Tox predictions? |
| cord-252166-qah877pk | More broadly, will in silico pharmacology ever be able to replace entirely experimental approaches in vitro and even in vivo, as some animal rights activists want us to believe? |
| cord-252166-qah877pk | While we are seeing a closer interaction between computational and in vitro approaches to date, will we see a similar relationship with in vivo studies in the future? |
| cord-018714-i291z2ju | How is HHV-6 acquired? |
| cord-018714-i291z2ju | What are the targets of cell- mediated cytotoxicity? |
| cord-018714-i291z2ju | a brief report In vitro interferon- gamma release test in the diagnosis of druginduced erythema nodosum Drug induced psoriasis Advances in the diagnosis of drug eruptions Baboon syndrome resulting from systemic drugs: is there strife between SDRIFE and allergic contact dermatitis syndrome? |
| cord-317435-4yuw7jo3 | Putting the patient back together- social medicine, network medicine, and the limits of reductionism The$ 2.6 billion pill- methodologic and policy considerations silico oncology drug repositioning and polypharmacology Individualized network- based drug repositioning infrastructure for precision oncology in the panomics era Drug repurposing: new treatments for Zika virus infection? |
| cord-317435-4yuw7jo3 | its possible role in the management of viral infections- a brief review Melatonin in bacterial and viral infections with focus on sepsis: a review Ebola virus disease: potential use of melatonin as a treatment One molecule, many derivatives: a never- ending interaction of melatonin with reactive oxygen and nitrogen species? |
| cord-304506-6el2ryl8 | How do aminoadamantanes block the influenza M2 channel, and how does resistance develop? |
| cord-318048-6nvi63rq | All rights reserved What is the current knowledge on the topic? |
| cord-318048-6nvi63rq | What question did this study address? |
| cord-322885-ob5euspo | Gold mine or just a bigger haystack? |
| cord-315702-pn8247j2 | What do we know about remdesivir drug interactions? |
| cord-292041-a65kfw80 | Has patient technique improved over time? |
| cord-292041-a65kfw80 | Phase I clinical trial of fenretinide( NSC374551) in advanced solid tumors Quis Custodiet Ipsos Custodes? |
| cord-292041-a65kfw80 | Sci Targeting the Endocytic Pathway and Autophagy Process as a Novel Therapeutic Strategy in COVID-19 SKP2 attenuates autophagy through Beclin1-ubiquitination and its inhibition reduces MERS- Coronavirus infection Autophagy and viruses: Adversaries or allies? |
| cord-321230-b5a1z14w | The impact of HCV SVR from direct acting antiviral and interferon- based treatments on mortality in a large population based cohort study Changes in synthetic opioid involvement in drug overdose deaths in the United States Known fentanyl use among clients of harm reduction sites in British Columbia What is killing people with hepatitis C virus infection? |
| cord-275827-r86ygqmy | : Should we generalize them? |
| cord-275827-r86ygqmy | A capture- recapture method for estimating the incidence of off- label prescriptions: the example of baclofen for alcohol use disorder in France Identification and tracking of Addictovigilance signals in general practice: which interactions between the general practitioners and the French Addictovigilance Network? |
| cord-275827-r86ygqmy | Results of a population- based cohort study in France Drug abuse monitoring: which pharmacoepidemiological resources at the European level? |
| cord-034406-i1hbx3pz | Ansun Biopharma enrolls first patient in proof of concept trial of DAS181 for the treatment of COVID-19 Direct administration in the respiratory tract improves efficacy of broadly neutralizing anti- influenza virus monoclonal antibodies In a murine model of acute lung infection, airway administration of a therapeutic antibody confers greater protection than parenteral administration Challenges and future prospects for the delivery of biologics: oral mucosal, pulmonary, and transdermal routes Non- invasive delivery strategies for biologics Idealhalers versus realhalers: is it possible to bypass deposition in the upper respiratory tract? |
| cord-034406-i1hbx3pz | I- particles of sugar excipients( trehalose and raffinose) for protein delivery Dry powders of stable protein formulations from aqueous solutions prepared using supercritical CO2-assisted aerosolization Mechanisms of protein stabilization in the solid state Stabilisation of proteins via mixtures of amino acids during spray drying Amorphous powders for inhalation drug delivery PEGylation, an approach for improving the pulmonary delivery of biopharmaceuticals What is the future of PEGylated therapies? |
| cord-034406-i1hbx3pz | Protalix BioTherapeutics Designing inhaled protein therapeutics for topical lung delivery: what are the next steps? |
| cord-034406-i1hbx3pz | The inhibition of phagocytosis of respirable microspheres by alveolar and peritoneal macrophages Distribution and cellular uptake of PEGylated polymeric particles in the lung towards cell- specific targeted delivery Drug delivery for tuberculosis: is inhaled therapy the key to success? |
| cord-034406-i1hbx3pz | The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non- adhesive polymer nanoparticles Preclinical models for pulmonary drug delivery Formulation technology to repurpose drugs for inhalation delivery Will pulmonary drug delivery for systemic application ever fulfill its rich promise? |
| cord-314827-yqr7110e | /OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/ STAT3 regulation Treatment with a new benzimidazole derivative bearing a pyrrolidine side chain overcomes sorafenib resistance in hepatocellular carcinoma Non- coding RNAs: emerging regulators of sorafenib resistance in hepatocellular carcinoma New knowledge of the mechanisms of sorafenib resistance in liver cancer Loss of hepatic NF- kB activity enhances chemical hepatocarcinogenesis through sustained c- Jun N- terminal kinase 1 activation Molecular therapies in hepatocellular carcinoma: what can we target? |
| cord-314827-yqr7110e | A lateral approach to traditional drug discovery? |
| cord-328559-2qvxw896 | What is the impact of mental health- related stigma on help- seeking? |
| cord-334170-85x5vmyi | Can treatments for hypertension be repurposed for the treatment of dementia? |
| cord-284479-75zgljet | Can you teach old drugs new tricks? |
| cord-284479-75zgljet | How Far Are We? |
| cord-284479-75zgljet | Luciferase- expressing Ebolaviruses as tools for screening of antivirals Emerging virus diseases: can we ever expect the unexpected? |
| cord-265699-0socw0hp | -Where do you draw the line? |
| cord-265699-0socw0hp | Dendrimers with tetrabenzoporphyrin cores: Near infrared phosphors for in vivo oxygen imaging Dendrimers for theranostic applications Dendrimer- protein interactions versus dendrimer- based nanomedicine Dendrimers as drug carriers: Applications in different routes of drug administration Dendrimers as drug delivery vehicles: Non- covalent interactions of bioactive compounds with dendrimers Association of chemotherapeutic drugs with dendrimer nanocarriers: An assessment of the merits of covalent conjugation compared to noncovalent encapsulation Dendrimers for gene delivery- a potential approach for ocular therapy? |
| cord-265699-0socw0hp | Reality or utopia? |
| cord-265699-0socw0hp | Where should we invest our resources and efforts? |
| cord-321741-aq76s37x | JNJ872 inhibits influenza A virus replication without altering cellular antiviral responses Topical application of aminoglycoside antibiotics enhances host resistance to viral infections in a microbiota- independent manner T7 RNA polymerase- dependent and-independent systems for cDNA- based rescue of Rift Valley fever virus Animal models of Chikungunya virus infection and disease Emerging virus diseases: can we ever expect the unexpected? |
| cord-273656-xo82zyi6 | The Catalyst Paying for prescription drugs around the world: why is the U.S. an outlier? |
| cord-273656-xo82zyi6 | Too Low? |
| cord-273656-xo82zyi6 | While cisatracurium is the agent of choice for many institutions, in the setting of drug shortages, consider reserving cisatracurium( and atracurium) for patients with endorgan dysfunction and use vecuronium or rocuronium when both kidney and liver function are preserved Addressing the global shortage of, and access to, medicines and vaccines Report by the Director- General BACKGROUND Medicines shortages: Global approaches to addressing shortages of essential medicines in health systems Medicine shortages: Gaps between countries and global perspectives Essential ICU drug shortages for COVID-19: what can frontline clinicians do? |
| cord-273656-xo82zyi6 | Why are there so many drug shortages? |
| cord-354180-6esn3t2b | How to provide a regulated supply of pharmaceutical- grade opioids that is accessible, scalable and will attract people who are most at risk of overdose? |
| cord-022082-1dq623oe | A toxicological study Epididymal and systemic phospholipidosis in rats and dogs treated with the dopamine D3 selective antagonist PNU-177864 Myopathy related to administration of a cationic amphiphilic drug and the use of multidose drug distribution analysis to predict its occurrence Drug- induced phospholipidosis: are there functional consequences? |
| cord-022082-1dq623oe | The specificity of the high endothelial venule in bronchus- associated lymphoid tissue( BALT) T cells and T cell subsets in rat bronchus associated lymphoid tissue( BALT) in situ and in suspension Have you seen this?' |
| cord-022082-1dq623oe | Two distinct patterns Interstitial pneumonitis associated with bleomycin therapy Bleomycin lung toxicity: who are the patients with increased risk? |
| cord-022082-1dq623oe | What are the imphcations for humans of drugs that induce phosphohpidosis in laboratory animals? |
| cord-022082-1dq623oe | What can the biology of small cell cancer of the lung teach us about the endocrine lung? |
| cord-260215-gsnjlhjd | Are outcomes the same with all dry powder inhalers? |
| cord-260215-gsnjlhjd | Inhaled antibiotics: dry or wet? |
| cord-260215-gsnjlhjd | Inhaled bronchodilator administration during mechanical ventilation: how to optimize it, and for which clinical benefit? |
| cord-260215-gsnjlhjd | Is inhalation rate important for a dry powder inhaler? |
| cord-324166-6ydn2bvy | A synergistic combination for COVID-19 chemoprophylaxis and treatment? |
| cord-324166-6ydn2bvy | Individualized networkbased drug repositioning infrastructure for precision oncology in the panomics era Drug repurposing: New treatments for zika virus infection? |
| cord-321657-2s1npse5 | Could this be the reason for the observed higher severity rate among older patients? |
| cord-299424-qy3lccjq | Na+ channel function in epicardial border zone cells that survive in the infarcted canine heart? |
| cord-299424-qy3lccjq | New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? |
| cord-299424-qy3lccjq | The role of autophagy in the heart Is autophagy in response to ischemia and reperfusion protective or detrimental for the heart? |
| cord-329318-eo8auo1f | While We Wait for a Vaccine Against SARS- CoV-2, Why Not Think About Available Drugs? |
| cord-299911-v95pf3eg | Pregnane X receptor is required for interleukin-6-mediated down- regulation of cytochrome P450 3A4 in human hepatocytes Is nuclear factor kappa- B the missing link between inflammation, cancer and alteration in hepatic drug metabolism in patients with cancer? |
| cord-299911-v95pf3eg | anti- inflammatory strategies COVID-19: combining antiviral and antiinflammatory treatments Immunosuppression for hyperinflammation in COVID-19: a double- edged sword? |
| cord-299911-v95pf3eg | why and how? |
| cord-289382-bnl9i9oy | : a molecular, biological, and epidemiological study Has the era of untreatable infections arived? |
| cord-289382-bnl9i9oy | Where can I go for more information? |
| cord-289382-bnl9i9oy | where does it come from and what can we do about it? |
| cord-311730-189vax2m | What does it offer? |
| cord-311730-189vax2m | and why might it be effective in the treatment of COVID-19? |
| cord-285121-3cjr1rol | A synergistic combination of curcumin, epicatechin gallate and resveratrol, repolarizes tumor- associated Microglia/ Macrophages, and eliminates glioblastoma( GBM) and GBM stem cells Long- term use of an antiinflammatory, curcumin, suppressed type 1 immunity and exacerbated visceral leishmaniasis in a chronic experimental model Curcumin induces glioma stem- like cell formation Targeting breast stem cells with the cancer preventive compounds curcumin and piperine Antioxidant polyphenols in cancer treatment: friend, foe or foil? |
| cord-285121-3cjr1rol | Can you teach old drugs new tricks? |
| cord-285121-3cjr1rol | chemical con artists foil drug discovery Can invalid bioactives undermine natural product- based drug discovery? |
| cord-285121-3cjr1rol | inhibits epithelial- mesenchymal transition and tumor growth in cisplatin- resistant triple- negative breast cancer Thioridazine: resurrection as an antimicrobial agent? |
| cord-015334-8p124rwp | It is impossible to analyse a nonresponse of our recommendations: is our advice even red, is it considered as inadequate? |
| cord-015334-8p124rwp | What are the experiences of patients? |
| cord-015334-8p124rwp | What does current information provision on antidepressants to patients with a depression admitted to a psychiatric hospital look like? |
| cord-015334-8p124rwp | What is the current practice of health care professionals? |
| cord-015334-8p124rwp | anti- References Simultaneous determination of olanzapine, clozapine and demethylated metabolites in serum by on- line column- switching Comparative study and optimisation of the administration mode of three proton pump inhibitors by nasogastric tube Is the administration of esomeprazole through a nasogastric tube modified by concomitant delivery of a nutrition mixture? |
| cord-015334-8p124rwp | … where do we stand? |
| cord-255460-r5p5helx | ( HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple- negative or BRCA1/2 mutation- associated breast cancer Use of complementary and alternative medicine and breast cancer survival in the Health, eating, activity, and lifestyle study Breast cancer management: past, present and evolving Serendipity in cancer drug discovery: rational or coincidence? |
| cord-255460-r5p5helx | A phase II study Can the pharmaceutical industry reduce attrition rates? |
| cord-255460-r5p5helx | Can you teach old drugs new tricks? |
| cord-255460-r5p5helx | Recent advances in drug repositioning for the discovery of new anticancer drugs Drug repurposing in malignant pleural mesothelioma: a breath of fresh air? |
| cord-255460-r5p5helx | is repurposing the future of drug discovery research? |
| cord-303555-mwu72q7w | A Crucial Role in the Action of Insulin, EGF, and pp60src? |
| cord-303555-mwu72q7w | The MEK Kinases MEKK4/ Ssk2p Facilitate Complexity in the Stress Signaling Responses of Diverse Systems Upstream Regulators of the c- Jun Amino- Terminal Kinases? |
| cord-303555-mwu72q7w | The first question the academic investigator should ask is, in their hands, does the dose- response effect on tumor cell growth/ viability correspond to the claimed inhibitory IC50 of the compound against its purified specific target? |
| cord-303555-mwu72q7w | The first thing the independent academic collaborator needs to know is what was the highest safe dose of the compounds used in prior mouse studies? |
| cord-297010-imciixde | Can you teach old drugs new tricks? |
| cord-297010-imciixde | EUA chloroquine phosphate health care provider fact sheet EUA hydroxychloroquine sulfate health care provider fact sheet Effects of chloroquine on viral infections: an old drug against today's diseases? |
| cord-297010-imciixde | revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy Chloroquine and hydroxychloroquine binding to melanin: some possible consequences for pathologies Increased incidence of gastrointestinal side effects in patients taking hydroxychloroquine: a brand- related issue? |
| cord-348102-k0s9j9sz | A novel coronavirus from patients with pneumonia in China COVID-19 infection in cancer patients: how can oncologists deal with these patients? |
| cord-325315-m3do6t1j | authors: Rossi, Carlo Maria; Beretta, Flavio Niccolò; Traverso, Grazia; Mancarella, Sandro; Zenoni, Davide title: A case report of toxic epidermal necrolysis( TEN) in a patient with COVID-19 treated with hydroxychloroquine: are these two partners in crime? |
| cord-325315-m3do6t1j | gold Open Access which fosters wider collaboration and increased citations maximum visibility for your research Ready to submit your research? |
| cord-313268-j51zyodw | Indomethacin has a potent antiviral activity against SARS coronavirus as adjuvant treatment for coronavirus disease 2019 pneumonia patients requiring hospitalization( MAC-19 PRO): a case series Beneficial actions of melatonin in the management of viral infections: a new use for this ″molecular handyman″? |
| cord-313268-j51zyodw | Phase II study Prostate cancer and prostatic intraepithelial neoplasia: true, true, and unrelated? |
| cord-355971-99mhacqa | : what can we safely use? |
| cord-347986-ds5hm731 | In the event of such a pandemic should arise, where do we stand in treating and preventing the spread of this virus? |
| cord-349682-kpg0vley | ) A Study of a Candidate COVID-19 Vaccine( COV001) Can a century- old TB vaccine steel the immune system against the new coronavirus? |
| cord-323940-ubazgvov | The trinity of COVID-19: immunity, inflammation and intervention The pathogenesis and treatment of the` Cytokine Storm'in COVID-19 The eye as the discrete but defensible portal of coronavirus infection Effects of chloroquine on viral infections: an old drug against today's diseases? |
| cord-323940-ubazgvov | what to expect for COVID-19? |
| cord-331633-ix5un6c9 | Part I- Clinical Trials Legislation and Good Manufacturing Practices( GMP) of Nanotherapeutics in the EU Delivery systems for antimicrobial peptides Antimicrobial peptides Antimicrobial peptides: An alternative for innovative medicines? |
| cord-331633-ix5un6c9 | Resistance Is Futile? |
| cord-353572-b4mdiont | -Social medicine, network medicine, and the limits of reductionism The$ 2.6 billion pill-- methodologic and policy considerations silico oncology drug repositioning and polypharmacology Individualized network- based drug repositioning infrastructure for precision oncology in the panomics era Drug repurposing: New treatments for Zika virus infection? |
| cord-330380-wnbyy1gk | Kir2.2 PIP2 is a necessary cofactor for ion channel function: how and why? |
| cord-330380-wnbyy1gk | Why are oseltamivir and zanamivir effective against the newly emerged influenza A virus( A/ H1N1)? |
| cord-264867-ezsy76mx | A computational study Healing of perineal Crohn's disease with metronidazole Is metronidazole carcinogenic? |
| cord-264867-ezsy76mx | Based on the AlN and BN Nanoclusters: DFT Studies P) nanocages for drug- delivery systems? |
| cord-264867-ezsy76mx | How do carbon nanotubes serve as carriers for gemcitabine transport in a drug delivery system? |
| cord-264867-ezsy76mx | In situ characterization of electrochemical processes in one dimensional nanomaterials for energy storages devices Nanomaterials at work in biomedical research Are carbon nanotubes safe? |
| cord-264867-ezsy76mx | Process research and development of a dihydropyrimidine dehydrogenase inactivator: Large- scale preparation of eniluracil using a sonogashira coupling 5-Fluorouracil: Mechanisms of resistance and reversal strategies Screening of the structural, topological, and electronic properties of the functionalized Graphene nanosheets as potential Tegafur anticancer drug carriers using DFT method Recent and new targets for small molecule anti- cancer agents How strong is the edge effect in the adsorption of anticancer drugs on a graphene cluster? |
| cord-264867-ezsy76mx | the only possible cause? |
| cord-353524-3w970ycx | Therefore, is there a hope for a Q11 rapid drug to come to the market? |
| cord-353524-3w970ycx | What are the issues and chances for a rapid approval of a new medicine to treat COVID-19? |
| cord-293860-6kz0iws6 | A real- time dashboard of clinical trials for COVID-19 Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury Immunosuppression for hyperinflammation in COVID-19: a double- edged sword? |
| cord-293860-6kz0iws6 | Can we use interleukin-6( IL-6) blockade for coronavirus disease 2019( COVID-19)-induced cytokine release syndrome( CRS)? |
| cord-293860-6kz0iws6 | Is ethnicity linked to incidence or outcomes of covid-19? |
| cord-293860-6kz0iws6 | WHO Clinical Characterisation Protocol Are more black, Asian and minority ethnic people dying with Covid-19 than might be expected? |
| cord-293860-6kz0iws6 | Why tocilizumab could be an effective treatment for severe COVID-19? |
| cord-266294-ua22udlc | Are disulfiram- like reactions associated with abacavir- containing antiretroviral regi mens in clinical practice? |
| cord-266294-ua22udlc | Does it still have a role? |
| cord-266294-ua22udlc | Is acyclovir involved? |
| cord-266294-ua22udlc | Pharmacokinetic evaluation of the effects of ribavirin on zidovudine triphosphate formation: ACTG 5092s Study Team Efficacy and safety of tenofovir double- dose in treatment- experi enced HIV- infected patients: the TENO PLUS study Castillo Muñoz A, toxicity in HIV- infected subjects: a rando- Baños Roldán U, Artacho Criado S. Analisis mized, controlled study Increased haemoglobin A2 percentage in HIV infection: disease or treatment? |
| cord-266294-ua22udlc | Rôle de l'acy clovir? |
| cord-266294-ua22udlc | a pharmacokinetics, efficacy and safety review Once- daily dosing of nevirapine in HAART Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV- infected patients concurrently receiving nevirapine- based antiretroviral therapy and fluconazole Phar macokinetics of darunavir( TMC114) and atazanavir during coadministration in HIVnegative, healthy volunteers Alo pecia associated with ritonavir- boosted ata zanavir therapy Pharmacokinetic interaction between rifampicin and ritonavir- boosted atazanavir in HIV- infected patients Increased incidence of cutaneous mycoses after HAART initiation: a benign form of immune reconstitution disease? |
| cord-007798-9ht7cqhu | : Are we forcing gastric content beyond the pylorus? |
| cord-007798-9ht7cqhu | A comparison of physostigmine and benzodiazepines for the treatment of anticholinergic poisoning Physostigmine: Is there a role for this antidote in pediatric poisonings? |
| cord-007798-9ht7cqhu | A randomized clinical trial of activated charcoal for the routine management of oral drug overdose How feasible is it to conform to the European guidelines on administration of activated charcoal within one hour of an overdose? |
| cord-007798-9ht7cqhu | Could the[ 13 C]methionine breath test be useful to assess liver mitochondrial function? |
| cord-007798-9ht7cqhu | Final report of a multicenter study Digoxin- specific Fab fragments as single first- line therapy in digitalis poisoning The use of digoxin- specific Fab fragments for severe digitalis intoxication in children Review of clinical experience with digoxin immune Fab( ovine) Digoxin- specific antibody fragments: How much and when? |
| cord-007798-9ht7cqhu | Science review: Carnitine in the treatment of valproic acid- induced toxicity-What is the evidence? |
| cord-351185-3y3gou6v | flickers steer cell migration Role of Platelets in Leukocyte Recruitment and Resolution of Inflammation Triggering the Resolution of Immune Mediated Inflammatory Diseases: Can Targeting Leukocyte Migration Be the Answer? |
| cord-275828-c6d6nk7x | How common is human toxocariasis? |
| cord-275828-c6d6nk7x | How good is the evidence for the recommended empirical antimicrobial treatment of patients hospitalized because of community- acquired pneumonia? |
| cord-275828-c6d6nk7x | How much isoniazid is needed for prevention of tuberculosis among immune competent adults? |
| cord-275828-c6d6nk7x | Is bacterial tracheitis changing? |
| cord-275828-c6d6nk7x | What is health- care associated pneumonia, and how should it be treated? |
| cord-329881-9vnz5zzg | However, before vaccination was discovered, how did people deal with the illness? |
| cord-329881-9vnz5zzg | Redeploying plant defences Investigations on plant antibiotics; studies on allicin, the antibacterial principle of Allium sativum( garlic) What does plant- based vaccine technology offer to the fight against COVID-19? |
| cord-329881-9vnz5zzg | What does welfare economics say? |
| cord-332038-icyut3xa | An updated overview and pharmacotherapeutics Mers: South Korea closes 700 schools after third death Severe respiratory disease associated with Middle East respiratory syndrome coronavirus Interaction of ethambutol with human organic cation transporters of the SLC22 family indicates potential for drug- drug interactions during antituberculosis therapy Screening of an FDA- approved compound library identifies four small- molecule inhibitors of Middle East respiratory syndrome corona virus replication in cell culture Effects of chloroquine on viral infections: an old drug against today's diseases? |
| cord-332038-icyut3xa | The renin- angiotensin system and antihypertensive drugs in Alzheimer's disease: Current standing of the angiotensin hypothesis? |
| cord-332038-icyut3xa | Time to share evidence and decision- making with patients? |
| cord-334881-x9nxxled | 2020-medrxiv Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS- CoV Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open- label non- randomized clinical trial FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease Prospects in Connective Tissue Diseases COVID-19 and diabetes: Can DPP4 inhibition play a role? |
| cord-334881-x9nxxled | The effectiveness of an anti- human IL-6 receptor monoclonal antibody combined with chemotherapy to target colon cancer stem- like cells International Guidelines on Radiation Therapy for Breast Cancer During the COVID-19 Pandemic Nivolumab combined with ruxolitinib: antagonism or synergy? |
| cord-334881-x9nxxled | cancermedicalscience COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting?. |
| cord-334881-x9nxxled | whatnext? |
| cord-320172-qw47pf9r | Immunohistologic analysis of the T- cell and macrophage infiltrate in 1,2-dimethylhydrazine- induced colon tumors in the rat Turnover of brush- border glycoproteins in human intestinal absorptive cells: Do lysosomes have regulatory function? |
| cord-320172-qw47pf9r | Is ethanol- induced damage of the gastric muosa a hyperosmotic effect? |
| cord-354006-j1y42oxu | For instance, what are the implications of a biotechnology company attempting to develop a metabolomics- based, non- genetic'dynamic phenotyping biomarker'for a gene patented hitherto for a static genotyping test to predict drug response or toxicity? |
| cord-354006-j1y42oxu | What will be the role of theragnostic patents in upstream and downstream biomarker research? |
| cord-354006-j1y42oxu | What will be the role of theragnostic patents in upstream and downstream biomarker research? |
| cord-274307-kl0uvrbw | How can we reconcile this irruption in the public or political debate and the maintenance of a sufficient level of expertise to avoid falling into the populism we know in other fields, with its share of false or truncated information? |
| cord-274307-kl0uvrbw | If tomorrow a vaccine or treatment against coronavirus is found, will we witness a war between states to control supply, as happened with masks? |
| cord-274307-kl0uvrbw | Is it necessary, because it is urgent, to abandon all the scientific principles of clinical trials that have previously led to undeniable therapeutic progress? |
| cord-274307-kl0uvrbw | Will drug policy tomorrow become a subject of electoral debate, on a par with fiscal or educational policy, and an argument for economic nationalism? |
| cord-274307-kl0uvrbw | Will the ability to control drug policy in all its aspects( innovation, rapid assessment, production) become a diplomatic weapon or even a propaganda tool for external or internal propaganda? |
| cord-274307-kl0uvrbw | Will the world balance between states be altered? |
| cord-274307-kl0uvrbw | authors: Bordet, Régis title: Is the drug a scientific, social or political object? |
| cord-317993-012hx4kc | : What are the barriers? |
| cord-317993-012hx4kc | Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications Will pulmonary drug delivery for systemic application ever fulfill its rich promise? |
| cord-317993-012hx4kc | The Role of the Primary Care Physician Organoids as a model system for studying human lung development and disease Device use errors with soft mist inhalers: A global systematic literature review and meta- analysis Irregular and Ineffective: A Quantitative Observational Study of the Time and Technique of Inhaler Use Problems with inhaler use: A call for improved clinician and patient education Inhalers: To switch or not to switch? |
| cord-317993-012hx4kc | Vitro Non- Animal Models? |
| cord-317993-012hx4kc | What can Dictyostelium bring to the study of Pseudomonas infections? |
| cord-326922-bajpr5a2 | : where are we heading? |
| cord-326922-bajpr5a2 | An outbreak of postoperative gram- negative bacterial endophthalmitis associated with contaminated trypan blue ophthalmic solution Eye opening: are compounded drugs causing harm? |
| cord-326922-bajpr5a2 | Compounding pharmacies: a viable option, or merely a liability? |
| cord-326922-bajpr5a2 | Time for compounding certification? |
| cord-326922-bajpr5a2 | United States Food and Drug Administration United States Food and Drug Administration Compounded drugs: are customized prescription drugs a salvation, snake oil, or both? |
| cord-316792-89f8g0m8 | Do the potential benefits outweigh the risks? |
| cord-316792-89f8g0m8 | How ow? |
| cord-316792-89f8g0m8 | The emergence of macrocyclic lactone resistance in the canine heartworm, Dirofilaria immitis Multiple drug resistance in the canine hookworm Ancylostoma caninum: an emerging threat? |
| cord-316792-89f8g0m8 | The venom optimization hypothesis revisited Combinatorial peptide libraries in drug design: lessons from venomous cone snails Were arachnids the first to use combinatorial peptide libraries? |
| cord-316792-89f8g0m8 | crawling biochemists with diverse toxin pharmacopeias Entomo- venomics: the evolution, biology and biochemistry of insect venoms Pharmacology and biochemistry of spider venoms Venom composition and strategies in spiders: is everything possible? |
| cord-322915-zrjx31ev | : where did we go wrong? |
| cord-322915-zrjx31ev | The end of an era? |
| cord-322915-zrjx31ev | The future of cephalosporins business Infectious history Oceans: medicine chests of the future? |
| cord-322915-zrjx31ev | Where have all the antibiotic patents gone? |
| cord-345059-t6hojshj | : what's next? |
| cord-345059-t6hojshj | Advances in experimental medicine and biology Outrageous prices of orphan drugs: a call for collaboration Orphan drugs for rare diseases: is it time to revisit their special market access status? |
| cord-345059-t6hojshj | If a medicine is too expensive, should a hospital make its own? |
| cord-347579-aqgauumt | Assessing the impact of drug courts on provider- directed marketing efforts by manufactures of medications for the treatment of opioid use disorder America's favorite antidote: Drug- induced homicide in the age of the overdose crisis Potential risk window for opioid overdose related to treatment with extended- release injectable naltrexone Buprenorphine supply, access and quality: Where we have come and the path forward Deaths of despair and the future of capitalism Methadone treatment providers'views of drug court policy and practice: a case study of New York State Seeing through the public health smoke- screen in drug policy Outcome trajectories in drug court: Do all participants have drug problems? |
| cord-347579-aqgauumt | Can drug courts help to reduce prison and jail populations? |
| cord-347579-aqgauumt | Do drug courts reduce the use of incarceration? |
| cord-347579-aqgauumt | Drug courts are not the answer: toward a health- centered approach to drug use Drug- related deaths and mortality in Europe Drug courts: background, effectiveness, and policy issues for Congress To grow market share, a drug maker pitches its product to judges Trading one drug for another? |
| cord-256118-gxhhwqdd | , see how the world is round? |
| cord-256118-gxhhwqdd | How much do you have, I would ask? |
| cord-256118-gxhhwqdd | The effects of the War on Drugs on people who inject drugs( PWID) in rural Puerto Rico Hepatitis C serosorting among people who inject drugs in rural Puerto Rico Injection- related Hepatitis C serosorting behaviors among people who inject drugs: an urban/ rural comparison Hepatitis C virus serosorting in people who inject drugs: sorting out the details Stories of pain and the problem of AIDS prevention: Injection drug withdrawal and its effects on risk behavior Beyond prevention? |
| cord-256118-gxhhwqdd | The process of drug injection: applying ethnography to the study of HIV risk among IDUs Commentary on Harris& Rhodes: discouraging syringe re- use by addressing drug injectors'everyday suffering Puerto rican syndemics: opiates, overdoses, HIV, and the hepatitis C virus in a context of ongoing crisis To enroll or not to enroll? |
| cord-256118-gxhhwqdd | The promise of treatment as prevention for hepatitis C: Meeting the needs of people who inject drugs? |
| cord-256118-gxhhwqdd | a systematic and methodological review Risk of transmission associated with sharing drug injecting paraphernalia: analysis of recent hepatitis C virus( HCV) infection using cross- sectional survey data Sharing cookers and cottons are surrogates for drug sharing Drug sharing among heroin networks: implications for HIV and hepatitis B and C prevention Social capital or networks, negotiations, and norms? |
| cord-256118-gxhhwqdd | gold Open Access which fosters wider collaboration and increased citations maximum visibility for your research: over 100 M website views per year submit your research? |
| cord-256118-gxhhwqdd | hepatitis C Do practice approaches go far enough in shifting focus from the individual? |
| cord-309871-y17puao2 | A call for randomized controlled trials to test the efficacy of chloroquine and hydroxychloroquine as therapeutics against novel coronavirus disease( COVID-19) Macrolide treatment for COVID-19: will this be the way forward? |
| cord-309871-y17puao2 | COVID-19? |
| cord-309871-y17puao2 | In vivo and in vitro antimalarial properties of azithromycin- chloroquine combinations that include the resistance reversal agent amlodipine Killing of Staphylococcus aureus in murine macrophages by chloroquine used alone and in combination with ciprofloxacin or azithromycin Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases Use of chloroquine in viral diseases Evaluation of Ebola virus inhibitors for drug repurposing Effects of chloroquine on viral infections: an old drug against today's diseases? |
| cord-309871-y17puao2 | The potential inhibitory effect of antiparasitic drugs and natural products on P- glycoprotein mediated efflux Digoxin- hydroxychloroquine interaction? |
| cord-309871-y17puao2 | Why could this couple of antimalarial and antibiotic drugs be efficient for such a broad number of infectious diseases caused by so various pathogens such as parasites and intracellular bacteria or viruses? |
| cord-309871-y17puao2 | what to expect for COVID-19? |
| cord-257344-d13at1y5 | COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression Chloroquine and hydroxychloroquine as available weapons to fight COVID-19 New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? |
| cord-257344-d13at1y5 | Friend or Foe? |
| cord-257344-d13at1y5 | Hydroxychloroquine or chloroquine for treatment or prophylaxis of COVID-19: a living systematic review Safety of hydroxychloroquine in COVID-19 and other diseases: a systematic review and meta- analysis of 53 randomized trials Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID-19 Insights from nanomedicine into chloroquine efficacy against COVID-19 A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19 Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus( 2019-nCoV) in vitro Hydroxychloroquine- Induced Stevens- Johnson Syndrome in COVID-19: A rare Case Report Characterizing the adverse dermatologic effects of hydroxychloroquine: a systematic review American Pharmaceutical Association Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk Arbidol: a broad- spectrum antiviral compound that blocks viral fusion Arbidol as a broad- spectrum antiviral: an update Anti- HCV, nucleotide inhibitors, repurposing against COVID-19 Ribavirin's antiviral mechanism of action: lethal mutagenesis? |
| cord-257344-d13at1y5 | Promising Supportive Therapies in Severe Cases of COVID-19? |
| cord-257344-d13at1y5 | The origin, transmission and clinical therapies on coronavirus disease 2019( COVID-19) outbreak-an update on the status COVID-19-new insights on a rapidly changing epidemic The SARS, MERS and novel coronavirus( COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? |
| cord-257344-d13at1y5 | Why and to What Extent? |
| cord-257344-d13at1y5 | the Application of Lopinavir/ Ritonavir for the Treatment of COVID-19 Infected Pneumonia Monitored by Quantitative RT- PCR Patients of COVID-19 may benefit from sustained lopinavir- combined regimen and the increase of eosinophil may predict the outcome of COVID-19 progression Simultaneous population pharmacokinetic model for lopinavir and ritonavir in HIV- infected adults Should COVID-19 Concern Nephrologists? |
| cord-257344-d13at1y5 | the potential role of extracorporeal membrane oxygenation Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? |
| cord-302018-3rlya16w | Are there models for these recommendations? |
| cord-302018-3rlya16w | How to detect children with true penicillin allergy? |
| cord-302018-3rlya16w | Our first question is: who is labeled as drug allergic in the general population and what can be done to uncover true drug allergy? |
| cord-302018-3rlya16w | What are the benefits and dangers of a drug allergy label? |
| cord-302018-3rlya16w | What are the tools for the labeling or delabeling of a drug allergy? |
| cord-302018-3rlya16w | What is the current understanding of drug hypersensitivity and allergic reactions? |
| cord-302018-3rlya16w | What is the evidence for, and how can recommendations be made for labeling and delabeling? |
| cord-302018-3rlya16w | What is the practical approach to drug allergy labeling and delabeling? |
| cord-336554-n8n5ii5k | An analysis based on decade- long structural studies of SARS Do viral infections mimic bacterial sepsis? |
| cord-336554-n8n5ii5k | COVID-19 treatment by repurposing drugs until the vaccine is in sight Tissue specific up regulation of ACE2 in rabbit model of atherosclerosis by atorvastatin: role of epigenetic histone modifications ACE 2: more of Ang 1- 7 or less Ang II? |
| cord-336554-n8n5ii5k | COVID-19? |
| cord-336554-n8n5ii5k | Dexamethasone for COVID-19? |
| cord-336554-n8n5ii5k | Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS- CoV-2 RNA dependent RNA polymerase( RdRp): a molecular docking study Computational target- based drug repurposing of elbasvir, an antiviral drug predicted to bind multiple SARS- CoV-2 proteins COVID-19 and chronological aging: senolytics and other anti- aging drugs for the treatment or prevention of corona virus infection? |
| cord-336554-n8n5ii5k | an open- label, randomised, phase 2 trial Mechanisms of coronavirus cell entry mediated by the viral spike protein SARS- CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? |
| cord-334511-lx9608vy | : Is It Really$ 802 Million? |
| cord-334511-lx9608vy | How Much NMR Data Is Required to Determine a Protein- Ligand Complex Structure? |
| cord-334511-lx9608vy | Recent developments and new frontiers for targeting multi- protein complexes Screening protein- Single stranded RNA complexes by NMR spectroscopy for structure determination Intramolecularly stapled amphipathic peptides via a boron- sugar interaction Structure determination using solution NMR: Is it worth the effort? |
| cord-334511-lx9608vy | What Is the Question? |
| cord-334511-lx9608vy | Why not? |
| cord-023509-tvqpv6fp | A smoking gun? |
| cord-023509-tvqpv6fp | A study of the histological cell types of lung cancer in workers suffering from asbestosis in the United Kingdom Lung cancer cell type and asbestos exposure Histological type of lung carcinoma in asbestos cement workers and matched controls Incidence of lung cancer by histological type among asbestos cement workers in Denmark Lung cancer in asbestos cement workers in Denmark Asbestos and lung cancer in Glasgow and the west of Scotland Exposure to crocidolite and the incidence of different histological types of lung cancer Asbestos and lung cancer Asbestos and lung cancer: is it attributable to asbestosis or to asbestos fibre burden? |
| cord-023509-tvqpv6fp | Does aluminum smelting cause lung disease? |
| cord-023509-tvqpv6fp | Fine structural changes in the lungs following cardiopulmonary bypass Complement and the damaging effects of cardiopulmonary bypass Acute lung injury during cardiopulmonary bypass: are the neutrophils responsible? |
| cord-023509-tvqpv6fp | The new prescription: industrial injuries benefits for smokers? |
| cord-023509-tvqpv6fp | The quantitative risks of mesothelioma and lung cancer in relation to asbestos exposure Is asbestos or asbestosis the cause of the increased risk of lung cancer in asbestos workers? |
| cord-023509-tvqpv6fp | radiation therapy Hamman- Rich syndrome'primed'by radiation? |
| cord-023509-tvqpv6fp | the Himalayan highlander adapted? |
| cord-023509-tvqpv6fp | the epidemiological evidence Do silica and asbestos cause lung cancer? |
| cord-325019-hznnoxw6 | , what was the dose response? |
| cord-325019-hznnoxw6 | Can statins improve neutrophil functions and clinical outcomes in COPD? |
| cord-325019-hznnoxw6 | Can you teach old drugs new tricks? |
| cord-325019-hznnoxw6 | Likewise, when researching new molecules in humans, it is necessary to ask several questions that could improve the designs, and avoid some failures, such as, for example, did the drug hit the target?, did the medication change the target? |
| cord-325019-hznnoxw6 | Likewise, when researching new molecules in humans, it is necessary to ask several questions that could improve the designs, and avoid some failures, such as, for example, did the drug hit the target?, did the medication change the target? |
| cord-325019-hznnoxw6 | The drug repurposing hub: a nextgeneration drug library and information resource Drug repositioning for COVID-19 Drug repurposing from the perspective of pharmaceutical companies Drug repurposing in cancer Drug Repurposing in anticancer reagent development Repurposing vitamin D as an anticancer drug Drug repurposing in Parkinson's disease Drug repurposing for viral infectious diseases: how far are we? |
| cord-325019-hznnoxw6 | and what are the characteristics of the study patients?. |
| cord-321379-7bpl5n3j | Are all the source data underlying the results available to ensure full reproducibility? |
| cord-321379-7bpl5n3j | Are all the source data underlying the results available to ensure full reproducibility? |
| cord-321379-7bpl5n3j | Are these known to be critical residues in the functioning of the main protease? |
| cord-321379-7bpl5n3j | Full Text Is the work clearly and accurately presented and does it cite the current literature? |
| cord-321379-7bpl5n3j | How was the-6 kcal/ mol free binding energy cut- off selected? |
| cord-321379-7bpl5n3j | If applicable, is the statistical analysis and its interpretation appropriate? |
| cord-321379-7bpl5n3j | Partly Is the study design appropriate and is the work technically sound? |
| cord-321379-7bpl5n3j | Yes Are sufficient details of methods and analysis provided to allow replication by others? |
| cord-351222-9bfchw4u | A marine natural product database Combining ethnopharmacology and virtual screening for lead structure discovery: COX- inhibitors as application example Computer- aided molecular selection and design of natural bioactive molecules Phytochemical databases of Chinese herbal constituents and bioactive plant compounds with known target specifities Strategies for efficient lead structure discovery from natural products Integrated in silico tools to exploit the natural products'bioactivity ADMET in silico modelling: towards prediction paradise? |
| cord-351222-9bfchw4u | Advances in drug research? |
| cord-351222-9bfchw4u | Drug research? |
| cord-351222-9bfchw4u | How does consensus scoring work for virtual library screening? |
| cord-351222-9bfchw4u | Molecular docking and high- throughput screening for novel inhibitors of protein tyrosine phosphatase-1B Rational selection of structurally diverse natural product scaffolds with favorable ADME properties for drug discovery Drugs? |
| cord-351222-9bfchw4u | The impact of informatics and computational chemistry on synthesis and screening Virtual screening: an effective tool for lead structure discovery? |
| cord-351222-9bfchw4u | Which in vitro screens guide the prediction of oral absorption and volume of distribution? |
| cord-006229-7yoilsho | But what would happen if the HFD was switched to normal pellet diet in these diabetic rats? |
| cord-006229-7yoilsho | Core or coating material? |
| cord-006229-7yoilsho | Increased GABA release in human neocortex at high intracellular sodium and low extracellular calcium-an anti- seizure mechanism?] |
| cord-006229-7yoilsho | Occasionally there are specific questions occurring on the ruminant xenobiotic metabolism: 1) are the observed metabolites ruminant specific and formed directly in the rumen? 2) are ruminants able to cleave plant specific metabolites like glycosides to the respective aglycon? |
| cord-006229-7yoilsho | Occasionally there are specific questions occurring on the ruminant xenobiotic metabolism: 1) are the observed metabolites ruminant specific and formed directly in the rumen? 2) are ruminants able to cleave plant specific metabolites like glycosides to the respective aglycon? |
| cord-006229-7yoilsho | The data point to a role of Rac1-regulated filamentous( nuclear?) |
| cord-006229-7yoilsho | The γH2AX Assay for Genotoxic and Nongenotoxic Agents: Comparison of H2AX Phosphorylation with Cell Death Response Perturbation of mitosis through inhibition of histone acetyltransferases: the key to ochratoxin a toxicity and carcinogenicity? |
| cord-006229-7yoilsho | Vitamin D metabolism-Involved in triazole fungicide toxicity? |
| cord-006229-7yoilsho | What dictates the uptake and translocation of nanoparticles in vitro? |
| cord-006229-7yoilsho | What would happen without this exception? |
| cord-287758-da11ypiy | ( COVID-19) Clinically Significant Drug Interactions with Cyclosporin Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late Endosome/ Lysosome and Block the Entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus( MERS- CoV), and Severe Acute Respiratory Syndrome Coronavirus( SARS- CoV) Discovery and development of safe- in- man broadspectrum antiviral agents Teicoplanin: an alternative drug for the treatment of COVID-19? |
| cord-287758-da11ypiy | : cord-287758-da11ypiy authors: Mônica Vitalino de Almeida, Sinara; Cleberson Santos Soares, José; Lima dos Santos, Keriolaine; Emanuel Ferreira Alves, Josival; Galdino Ribeiro, Amélia; Trindade Tenório Jacob, Íris; Juliane da Silva Ferreira, Cindy; Celerino dos Santos, Jéssica; Ferreira de Oliveira, Jamerson; Bezerra de Carvalho Junior, Luiz; do Carmo Alves de Lima, Maria title: COVID-19 therapy: what weapons do we bring into battle? |
| cord-287758-da11ypiy | A Review of Its Use in the Management of HIV-1 Infection Discovering drugs to treat coronavirus disease 2019( COVID-19) Therapeutic Options and Critical Care Strategies in COVID-19 Patients; Where Do We Stand in This Battle? |
| cord-287758-da11ypiy | A new trick for an old drug? |
| cord-287758-da11ypiy | Antiviral treatment of COVID-19 Hydroxychloroquine and ivermectin: A synergistic combination for COVID-19 chemoprophylaxis and treatment? |
| cord-287758-da11ypiy | Clinical course and outcomes of critically ill patients with SARS- CoV-2 pneumonia in Wuhan, China: a single- centered, retrospective, observational study Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? |
| cord-287758-da11ypiy | Engineering an antiviral for COVID-19? |
| cord-287758-da11ypiy | How Far Are We? |
| cord-287758-da11ypiy | The Use of Cyclosporine A in Rheumatology: a 2016 Comprehensive Review Cyclosporine A: a valid candidate to treat COVID-19 patients with acute respiratory failure? |
| cord-287758-da11ypiy | The possible mechanisms of action of 4-aminoquinolines( chloroquine/ hydroxychloroquine) against Sars- Cov-2 infection( COVID-19): A role for iron homeostasis? |
| cord-287758-da11ypiy | The world is facing a huge challenge in the coronavirus disease( COVID-19) pandemic: How to fight an enemy without weapons in terms of therapy? |
| cord-350703-vrqltz3s | For example, for an anti- DENV drug, in what cells and tissues does the virus replicate during the acute phase of infection in humans? |
| cord-350703-vrqltz3s | He will also provide a look ahead: what research is needed, where do we go from here? |
| cord-350703-vrqltz3s | How can ISAR members make use of our social media sites? |
| cord-350703-vrqltz3s | How could we engineer compounds to be selectively loaded onto these sites? |
| cord-350703-vrqltz3s | What are the principal diseases for which antivirals are needed? |
| cord-350703-vrqltz3s | What aspects have you found most satisfying? |
| cord-350703-vrqltz3s | What has been your own experience? |
| cord-350703-vrqltz3s | What is your personal experience with social networking and science? |
| cord-350703-vrqltz3s | What new approaches are you using in your research? |
| cord-351517-npcuo1ld | But who knows? |
| cord-351517-npcuo1ld | Can we correct the threat of liaisons dangereuses? |
| cord-351517-npcuo1ld | First, do these new drugs really improve survival? |
| cord-351517-npcuo1ld | Have we a solution to these potential liaisons dangereuses likely to work? |
| cord-351517-npcuo1ld | Otherwise one would seem to have wasted their time, energy and perhaps destroyed your marriage, missed your children growing up, both or perhaps something even worse( a fling in Cancun?). |
| cord-351517-npcuo1ld | Une liaison dangerous? |
| cord-351517-npcuo1ld | What is the P- value anyway? |
| cord-351517-npcuo1ld | What is the( p-) value of the pvalue? |
| cord-351517-npcuo1ld | key: cord-351517-npcuo1ld authors: Gale, Robert Peter; Lazarus, Hillard M. title: Liaisons Dangereuses? |
| cord-342588-berrojmq | Are the patients willing to accept HAT as a diagnosis anymore? |
| cord-342588-berrojmq | Can we overcome wrong dogma and information?and"Will patients falling into the respective category accept a lumbar puncture? |
| cord-342588-berrojmq | Can we overcome wrong dogma and information?and"Will patients falling into the respective category accept a lumbar puncture? |
| cord-342588-berrojmq | Is the medical staff that was told for over 100 years that HAT belongs into the specialized hands of the vertical programs willing to assume this task and challenge? |
| cord-342588-berrojmq | Is the medical staff willing to recognize a suspected case, given this will create a massive workload including trouble with the relatives of the patient and village, paperwork, an invasion of specialists for diagnosis and follow up activities? |
| cord-342588-berrojmq | Sleeping sickness- A growing problem? |
| cord-342588-berrojmq | The development of drugs for treatment of sleeping sickness: A historical review Epidemiology of human African trypanosomiasis Control of human African trypanosomiasis: Back to square one Sleeping sickness- A growing problem? |
| cord-342588-berrojmq | The skin is a significant but overlooked anatomical reservoir for vector- borne African trypanosomes The Dermis as a Delivery Site of Trypanosoma brucei for Tsetse Flies Do cryptic reservoirs threaten gambienses- leeping sickness elimination? |
| cord-342588-berrojmq | Therefore, the questions are:"will the disease be recognized by the younger physicians and nurses who have never seen a case of HAT?" |
| cord-342588-berrojmq | Whose Elimination? |
| cord-295807-68sukdb1 | A New Kid on the Block? |
| cord-295807-68sukdb1 | A quantitative study Stimulatory effect of insulin on renal proximal tubule sodium transport is preserved in type 2 diabetes with nephropathy Molecular Mechanism of Pancreatic and Salivary Glands Fluid and HCO3− Secretion Effect of mineralocorticoids on acid- base balance Bartter or Gitelman- how to differentiate? |
| cord-295807-68sukdb1 | Acute metabolic acidosis enhances circulating parathyroid hormone, which contributes to the renal response against acidosis in the rat Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis Carbonic anhydrase II deficiency in 12 families with the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification Mouse Models of SLC4-linked Disorders of HCO3-Transporter Dysfunction Effect of chronic carbonic anhydrase inhibitor therapy on bone mineral density in white women Can acetazolamide be used to treat diseases involving increased bone mineral density? |
| cord-295807-68sukdb1 | An Update Prevalence of depression and suicidal ideation increases proportionally with renal function decline, beginning from early stages of chronic kidney disease Carbon dioxide test as an additional clinical measure of treatment response in panic disorder Responses to hypercarbia induced by acetazolamide in panic disorder patients Increased lactate levels and reduced pH in postmortem brains of schizophrenics: medication confounds Possible alternatives to soda lime Absorption of carbon dioxide Interaction of inhalational anaesthetics with CO2 absorbents Hypercapnia and acidosis in sepsis: a double- edged sword? |
| cord-295807-68sukdb1 | Bicarbonate is essential for fertilization of mouse eggs: mouse sperm require it to undergo the acrosome reaction Factors and pathways involved in capacitation: how are they regulated? |
| cord-295807-68sukdb1 | K+ and Lac- distribution in humans during and after high- intensity exercise: role in muscle fatigue attenuation? |
| cord-295807-68sukdb1 | Na(+) regulation in the malaria parasite Plasmodium falciparum involves the cation ATPase PfATP4 and is a target of the spiroindolone antimalarials The Warburg Effect: How Does it Benefit Cancer Cells? |
| cord-295807-68sukdb1 | Outcome of surgical patients who present acidosis postoperatively Biochemical changes in stored donor units: implications on the efficacy of blood transfusion Clinical impact of blood storage lesions Influence of pH on wound- healing: a new perspective for wound- therapy? |
| cord-295807-68sukdb1 | Pharmacokinetics and pharmacodynamics of dichloroacetate in children with lactic acidosis due to severe malaria Can exchange transfusions using red blood cells from donors with Southeast Asian ovalocytosis prevent or ameliorate cerebral malaria in patients with multi- drug resistant Plasmodium falciparum? |
| cord-295807-68sukdb1 | The pathophysiologic and prognostic significance of acidosis in severe adult malaria Unidentified acids of strong prognostic significance in severe malaria Put a cork in it: Plugging the M2 viral ion channel to sink influenza Proton Pump Inhibitors are Risk Factors for Viral Infections: Even for COVID-19? |
| cord-295807-68sukdb1 | What Opportunities Exist for Better Treatment of Helicobacter pylori Infection in Children? |
| cord-295807-68sukdb1 | response to acetazolamide and postulated mechanisms Metabolic and hemodynamic consequences of sodium bicarbonate administration in patients with heart disease Cellular mechanisms of muscle fatigue Challenging the role of pH in skeletal muscle fatigue Lactic acid and exercise performance: culprit or friend? |
| cord-280158-3fhhuzg5 | Does repeating these strategies boarder on insanity? |
| cord-280158-3fhhuzg5 | If indeed antibiotic resistance( mutation- based drug resistance) is the major challenge; then, why have we not focused on identifying drug targets less prone to mutation- based resistance? |
| cord-280158-3fhhuzg5 | If indeed mutation- based drug resistance is the greatest impediment to the discovery effort, then why not work backwards from the problem as a discovery strategy? |
| cord-280158-3fhhuzg5 | If true, then should we focus efforts on subgroups of pathogens like Gram negative or positive bacteria only, anaerobic bacteria or other group where the range of common essential genes is likely greater?. |
| cord-280158-3fhhuzg5 | Is this evolution at work? |
| cord-280158-3fhhuzg5 | It raises another critical question"can we find drug targets that by catalytic mechanism are capable of escaping mutation- based drug resistance? |
| cord-280158-3fhhuzg5 | Structure based drug design has yielded therapeutics in other areas including HIV/ AIDS( protease inhibitors), antivirals( zanamivir for influenza), and even inhibitors of cyclooxygenase, so why not for antibacterials? |
| cord-280158-3fhhuzg5 | The failure of success? |
| cord-280158-3fhhuzg5 | We have to ask"how much are we willing to invest in order to get one new antibiotic to the clinic? |
| cord-280158-3fhhuzg5 | What does"antibiotic like"really mean anyway? |
| cord-280158-3fhhuzg5 | Where Do We Go? |
| cord-280158-3fhhuzg5 | Where to uncover? |
| cord-280158-3fhhuzg5 | Who will develop new antibacterial agents? |
| cord-280158-3fhhuzg5 | With scarce resources and many suggestions for how to find next generation antibiotics, where do you place your bets[ 3]? |
| cord-342756-rgm9ffpk | -What happens next? |
| cord-342756-rgm9ffpk | : what to expect for COVID-19? |
| cord-342756-rgm9ffpk | COVID-19 and diabetes: Can DPP4 inhibition play a role? |
| cord-342756-rgm9ffpk | COVID-19, SARS and MERS: are they closely related? |
| cord-342756-rgm9ffpk | DPP4 inhibition: preventing SARS- CoV-2 infection and/or progression of COVID-19? |
| cord-342756-rgm9ffpk | Protein- protein interactions of viroporins in coronaviruses and paramyxoviruses: new targets for antivirals? |
| cord-342756-rgm9ffpk | The importance of hypertension as a risk factor for severe illness and mortality in COVID-19 Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study Diabetes is a risk factor for the progression and prognosis of COVID-19 Older people and COVID-19: isolation, risk and ageism Asymptomatic carriers of COVID-19 as a concern for disease prevention and control: more testing, more follow- up Drug repositioning: identifying and developing new uses for existing drugs Drug repurposing from the perspective of pharmaceutical companies Drug repurposing: progress, challenges and recommendations Emerging virus diseases: can we ever expect the unexpected? |
| cord-342756-rgm9ffpk | and COVID-19: serendipity or opportunity for intervention? |
| cord-342756-rgm9ffpk | should inhibitors of the renin- angiotensin system be withdrawn in patients with COVID-19? |
| cord-342756-rgm9ffpk | what lessons have we learned? |
| cord-354445-lnvc7mmf | 1994, 1995, and 1996 APIC Guidelines Committee High- level disinfection or"sterilization"of endoscopes? |
| cord-354445-lnvc7mmf | 5-year review Is bacteriologic surveillance in endoscope reprocessing stringent enough? |
| cord-354445-lnvc7mmf | Antimicrobial efficacy of endoscopic disinfection procedures: a controlled, multifactorial investigation High- level disinfection of gastrointestinal endoscopes: are current guidelines adequate? |
| cord-354445-lnvc7mmf | Guideline for disinfection and sterilization in healthcare facilities Guideline for disinfection and sterilization of prion contaminated medical instruments Disinfection: is it time to reconsider Spaulding? |
| cord-354445-lnvc7mmf | Low- temperature sterilization technologies: do we need to redefine sterilization? |
| cord-354445-lnvc7mmf | Mycobacteria and glutaraldehyde: is high- level disinfection of endoscopes possible? |
| cord-354445-lnvc7mmf | Sites need to have a response plan in place regarding notification if culture shows organisms of concern on an endoscope that has been used on multiple patients( i.e., notify the patient, the doctor or both?) |
| cord-354445-lnvc7mmf | Transmission of hepatitis B and C viruses in outpatient settings Viral hepatitis transmission in ambulatory health care settings Guideline for isolation precautions: preventing transmission of infectious agents in healthcare settings Evaluation of the risk of transmission of bacterial biofilms and clostridium difficile during gastrointestinal endoscopy ERCP scopes: what can we do to prevent infections? |
| cord-354445-lnvc7mmf | What is disinfection, sterilization? |
| cord-354445-lnvc7mmf | [ 510(k)] submissions for liquid chemical sterilants/ high level disinfectants Are all sterilization processes alike? |
| cord-354445-lnvc7mmf | principles in gastrointestinal endoscopy Infectious disease complications of GI endoscopy: part II, exogenous infections ERCP scopes: what can we do to prevent infections? |
| cord-354445-lnvc7mmf | what can we do to prevent infections? |
| cord-354445-lnvc7mmf | where do we go from here? |
| cord-014687-0am4l5ms | : How Big a Problem is It? |
| cord-014687-0am4l5ms | : Where Are We Now? |
| cord-014687-0am4l5ms | A conversant? |
| cord-014687-0am4l5ms | Been a leader in science and application? |
| cord-014687-0am4l5ms | Been part of the dialogue that has been increasingly influential across all of Radiology, a conversation steeped in a deep tradition of excellence in diagnosis and treatment, and the safety and welfare of our children? |
| cord-014687-0am4l5ms | Can Time- Resolved Contrast- Enhanced MRA( TWIST) Classify Soft Tissue Vascular Anomalies in the Head and Neck in Children Accurately? |
| cord-014687-0am4l5ms | Does a Tertiary Care Radiologist Make a Difference? |
| cord-014687-0am4l5ms | Has he been part of the Pediatric Radiology landscape these last ten years? |
| cord-014687-0am4l5ms | Horizons, innovation, and the gift of en- abling … What else is needed to define a true pioneer? |
| cord-014687-0am4l5ms | How can we maintain and expand these relationships? |
| cord-014687-0am4l5ms | How was this done? |
| cord-014687-0am4l5ms | Imaging Followup of Lymphoma in Pediatric Patients: Is Pelvic CT Necessary? |
| cord-014687-0am4l5ms | Imaging Pulmonary Tuberculosis in Infants: What are the Most Useful Diagnostic Radiological Findings? |
| cord-014687-0am4l5ms | Is Dedicated Chest CT needed in Addition to PET CT for Evaluation of Pediatric Oncology Patients? |
| cord-014687-0am4l5ms | M.D. Why George Bisset? |
| cord-014687-0am4l5ms | Part of the dialogue? |
| cord-014687-0am4l5ms | Part of the landscape? |
| cord-014687-0am4l5ms | Part of the science and application? |
| cord-014687-0am4l5ms | Sonographic Evaluation of Pediatric Skeletal Lesions: Is it worthwhile? |
| cord-014687-0am4l5ms | Utility of Contrast- Enhanced MR Imaging in Children with Osteonecrosis: Does Gadolinium Help? |
| cord-014687-0am4l5ms | With these successes in mind, who better to embody the concept of bridging horizons that is the theme for this entire meeting? |
| cord-350571-6tapkjb6 | DI012: Wikipedia and medicines: who edits medicine articles on the English Wikipedia? |
| cord-350571-6tapkjb6 | Does a hospital formulary system impact timely medication administration and quality of inpatient care? |
| cord-350571-6tapkjb6 | From those who were treated by TMP/ SMX, following data were collected: age, gender, weight, doses, and indications( probabilistic? documented? |
| cord-350571-6tapkjb6 | From those who were treated by TMP/ SMX, following data were collected: age, gender, weight, doses, and indications( probabilistic? documented? |
| cord-350571-6tapkjb6 | From those who were treated by carbapenems, PIP/ TAZ or AMX AC, following data were collected: age, gender, weight, doses, indications( probabilistic? documented? |
| cord-350571-6tapkjb6 | From those who were treated by carbapenems, PIP/ TAZ or AMX AC, following data were collected: age, gender, weight, doses, indications( probabilistic? documented? |
| cord-350571-6tapkjb6 | HP- PC015: Discharged patients: a problem for community pharmacists? |
| cord-350571-6tapkjb6 | HP- PC027: QT- prolongation in an acute psychiatric setting: fact or fiction? |
| cord-350571-6tapkjb6 | HP- PC068: Are hospital pharmaceutical staff educated on the criticality of thermosensitive drugs? |
| cord-350571-6tapkjb6 | HP- PC134: How the centralization of medicines manufacturing enable to generalize the pharmaceutical validation? |
| cord-350571-6tapkjb6 | Mapping of the DLQI scores to EQ-5D utility values using ordinal logistic regression and Monte Carlo simulations: is it plausible? |
| cord-350571-6tapkjb6 | On the question''What is your general perception of the benefit of the clinical pharmacy service; for collaborating health professionals? |
| cord-350571-6tapkjb6 | Personal changes in drug regimen: dangerous for health system? |
| cord-350571-6tapkjb6 | The office of access to healthcare: how to optimize secured access to treatments? |
| cord-350571-6tapkjb6 | The open questions:''What disadvantages/ advantages have you experienced by the introduction of clinical pharmacist into multidisciplinary teams?''received 153/185 comments respectively. |
| cord-350571-6tapkjb6 | The research questions were: When comparing dicloxacillin with other antibiotics commonly used in children,( 1) is there a difference in the age of conversion from liquid to solid formulation and( 2) is there a difference in re- prescription rates on day 1 and 2 after the initial prescription? |
| cord-350571-6tapkjb6 | for the patient?''the total benefit was ranked 5.45 and 5.54 respectively( Scale from 0(''no benefit'') to 6(''beneficial to a very large extent''). |
| cord-265848-afkeuwup | ( 2) Will the patient's outcome likely be significantly better if the procedure is undertaken? |
| cord-265848-afkeuwup | ( 3) Are there acceptable alternatives to HD or HP? |
| cord-265848-afkeuwup | : is there a Tower of Babel bias? |
| cord-265848-afkeuwup | : is there a consensus on management? |
| cord-265848-afkeuwup | A review of the literature Lidocaine and rapid sequence intubation Acute asthma in emergency room Does ketamine have a role in managing severe exacerbation of asthma in adults? |
| cord-265848-afkeuwup | An evaluation of the effect of repeated doses of oral activated charcoal on salicylate elimination Does multiple- dose charcoal therapy enhance salicylate excretion? |
| cord-265848-afkeuwup | Continuous arterial- venous diahemofiltration and continuous veno- venous diahemofiltration in infants and children Functional characteristics of pediatric veno- venous hemofiltration Rapid removal of vancomycin by continuous veno- venous hemofiltration Is continuous veno- venous hemofiltration for acetaminophen- induced acute liver and renal failure worthwhile? |
| cord-265848-afkeuwup | Could the patient inadvertently have taken too much of a prescribed medication? |
| cord-265848-afkeuwup | Does the patient live alone, did he or she just lose a job, or have there been recent emotionally traumatic events? |
| cord-265848-afkeuwup | Evaluation of the use of an amphoteric solution as the rinsing product Is there a delay in bathing the external eye in the treatment of ammonia eye burns? |
| cord-265848-afkeuwup | How long after drug ingestion is activated charcoal still effective? |
| cord-265848-afkeuwup | How tightly can a drug be bound to a protein and still be removable by charcoal hemoperfusion in overdose cases? |
| cord-265848-afkeuwup | If it can be identified, is the substance nontoxic? |
| cord-265848-afkeuwup | In patients with head injuries who undergo rapid sequence intubation using succinylcholine, does pretreatment with a competitive neuromuscular blocking agent improve outcome? |
| cord-265848-afkeuwup | In patients with head injury undergoing rapid sequence intubation, does pretreatment with intravenous lignocaine/ lidocaine lead to an improved neurological outcome? |
| cord-265848-afkeuwup | Is surgical decontamination definitive treatment of"body- packers"? |
| cord-265848-afkeuwup | Is the patient eating a special diet or taking a new health food, alternative medication, or performance enhancer? |
| cord-265848-afkeuwup | Position statement and practice guidelines on the use of multi- dose activated charcoal in the treatment of acute poisoning Multiple doses of activated charcoal: time for reappraisal? |
| cord-265848-afkeuwup | The decision to transfer a patient for these therapies should rest on evaluation of several elements:( 1) Is the patient stable for transport? |
| cord-265848-afkeuwup | The demise of ipecac Poison Prevention: Poison treatment in the home Guideline on the use of ipecac syrup in the out- of- hospital management of ingested poisons Changes in arterial oxygen tension after gastric lavage for drug overdose Gastrointestinal tract perforation with charcoal peritoneum complicating orogastric intubation and lavage Esophageal tear following forceful removal of an impacted oral- gastric lavage tube Aspiration pneumonia following severe self- poisoning Position paper: gastric lavage Severe esophageal damage due to button battery ingestion: can it be prevented? |
| cord-265848-afkeuwup | The following questions may be revealing: What other medicines are in the house? |
| cord-265848-afkeuwup | The role of the Molecular Adsorbents Recirculating System( MARS) in the management of liver failure Preconditioning by extracorporeal liver support( MARS) of patients with cirrhosis and severe liver failure evaluated for living donor liver transplantation- a pilot study Application of MARS artificial liver support as bridging therapy before split liver retransplantation in a 15-month- old child Application of Molecular Adsorbent Recirculating System in patients with severe liver failure after hepatic resection or transplantation: initial single- centre experiences Experiences with MARS liver support therapy in liver failure: analysis of 176 patients of the International MARS Registry MARS preconditioning for living donor liver transplantation: panacea or placebo? |
| cord-265848-afkeuwup | What was the patient doing that day? |
| cord-265848-afkeuwup | When should dialysis be performed in lithium poisoning? |
| cord-265848-afkeuwup | an evaluation of indications and results Rapid correction of acute salt poisoning by peritoneal dialysis Toxicologic and pharmacokinetic evaluation of a case of vancomycin intoxication during continuous ambulatory peritoneal dialysis Use of peritoneal dialysis in experimental amphetamine poisoning Baclofen neurotxicity in uremic patients: is continuous ambulatory peritoneal dialysis less effective than intermittent hemodialysis? |
| cord-265848-afkeuwup | is hemodialysis really necessary? |
| cord-002774-tpqsjjet | ( 2) does participation in drug treatment programs increase social capital?, and( 3) is there a significant difference among treatment modalities in affecting change in~ial capital? |
| cord-002774-tpqsjjet | ( 2) does participation in drug treatment programs increase social capital?, and( 3) is there a significant difference among treatment modalities in affecting change in~ial capital? |
| cord-002774-tpqsjjet | Die: How to Save our Children? |
| cord-002774-tpqsjjet | Findings suggest that HM have less access t? |
| cord-002774-tpqsjjet | How can we Measure this Elusive Goal? |
| cord-002774-tpqsjjet | How do AIDS mortality and fatality rates vary when related community characteristics, such as household income, ethnic mix, and geographic access to primary and ancillary HIV/ AIDS services are considered? |
| cord-002774-tpqsjjet | How has the widespread availability of HAART( after 1996) impacted AIDS outcomes at the community level? |
| cord-002774-tpqsjjet | However, as part of an ongoing study? |
| cord-002774-tpqsjjet | In June 2004, the Association of? |
| cord-002774-tpqsjjet | Moreover, there is n? basis for assessing the impact of the resultant initiatives to improve health~onditions amo~ g~o":1":1um ties settled in unplanned areas. |
| cord-002774-tpqsjjet | Nearly all participants( 97%) reported a history of contact with drug llt.lnnent services( methadone maintenance, rehabilitation clinics and judicial treatment), mental health car? |
| cord-002774-tpqsjjet | Since urban areas are more than the aggregation? |
| cord-002774-tpqsjjet | System for Homeless, HIV- infected Patients in NYC? |
| cord-002774-tpqsjjet | The increase m parnc1pat10n, the CHR mvolvement in the community, and the positive feedback from the agen? |
| cord-002774-tpqsjjet | The moot question in all the above observed development are: has the city rationally addressed it planning needs? |
| cord-002774-tpqsjjet | The principle research questions were: 1) What is the relationship between the locations of areas with concentrations of PL WA and the distribution of both primary and ancillary service providers? |
| cord-002774-tpqsjjet | The quesuon to be explore.cl 1~: If health care is available and accessible to one person, what makes it not available to all people? |
| cord-002774-tpqsjjet | The research questions were: What are the effects of homelessness on health? |
| cord-002774-tpqsjjet | Two research questions were investigated: are there spatial patterns to the events dis · tribution, and moreover, are these patterns overlapping across space? |
| cord-002774-tpqsjjet | What kind of supports are needed for homeless people to get off the street? |
| cord-002774-tpqsjjet | When the govern · ment withdrew from direct service provision as reform trends and donor advocacy suggested, how does it perform its new indirect role of managing relations with new direct health services providers in terms of regulating, enabling, and managing relations with these health services providers? |
| cord-002774-tpqsjjet | When/(calen · dar time), By 2, fisher exact and t were appliedxwhom( authors?). |
| cord-002774-tpqsjjet | Who and Why? |
| cord-002774-tpqsjjet | Why children die in Bangladesh? |
| cord-002774-tpqsjjet | _ contacts these women via? |
| cord-002774-tpqsjjet | a report of the efforts being made towards such a goal: The paper descr~ bes~ c~ se study? |
| cord-002774-tpqsjjet | and dent~ I hygiene t? |
| cord-002774-tpqsjjet | blocks, we considered a broad range of factors including evidence of homogeneity an~ heterogeneity( socmeconomic, ethnic, housing type, environmental) across blocks within and blocks ad1acent to a nei.ghborhood, and across the 36 sample neighborhoods; the potential for efficient recruit · ment of appropriate particip.ants( i.e. sufficient local pedestrian traffic); and boundaries used in reporting census data( s? |
| cord-002774-tpqsjjet | cQue tenemos para aprender de las"soluciones"que ellos mismos encuenrran a los usos problemat1cos? |
| cord-002774-tpqsjjet | dema~~a? |
| cord-002774-tpqsjjet | en estas comunidades? |
| cord-002774-tpqsjjet | t) does social capital predict parti~ ipating in treatment programs? |
| cord-002774-tpqsjjet | to all pama~~g? |
| cord-002774-tpqsjjet | ~i~ an~ s were recruited from drop in centres in 7 cities across |
| cord-002774-tpqsjjet | ~ts: In addmon to reporting process data and descriptions of the SIF users, we report on data indicating that the establishment of the SIF has been independently associated with reductions in public~': ° g~( p |